Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Deoxycytidine
Epstein-Barr Virus Infections
Female
Herpesvirus 4, Human
Humans
Immunotherapy, Adoptive
Male
Middle Aged
Nasopharyngeal Neoplasms
Neoplasm Recurrence, Local
Quality of Life
T-Lymphocytes, Cytotoxic

authors with profiles

MALCOLM BRENNER
PREMAL LULLA